Citigroup Reiterates “Neutral” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “neutral” rating restated by analysts at Citigroup in a note issued to investors on Tuesday, Marketbeat Ratings reports. They presently have a $166.00 price target on the stock, down from their previous price target of $176.00. Citigroup’s price objective indicates a potential upside of 21.97% from the company’s previous close.

Other research analysts also recently issued research reports about the company. Chardan Capital reiterated a “buy” rating and set a $219.00 price target on shares of Krystal Biotech in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, July 25th. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Bank of America lowered their price target on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and an average target price of $210.22.

Krystal Biotech Stock Up 0.1%

Shares of KRYS traded up $0.10 during trading on Tuesday, reaching $136.10. 319,611 shares of the company traded hands, compared to its average volume of 334,502. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $207.84. The stock has a market cap of $3.93 billion, a PE ratio of 27.66 and a beta of 0.70. The stock has a 50-day simple moving average of $141.24 and a 200-day simple moving average of $155.67.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. On average, equities research analysts predict that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the firm’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares of the company’s stock, valued at approximately $216,924,382.80. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 49,800 shares of company stock valued at $7,487,943. Company insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Brooklyn Investment Group lifted its holdings in shares of Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after acquiring an additional 105 shares during the last quarter. Twin Tree Management LP bought a new position in Krystal Biotech in the 1st quarter worth about $29,000. Fifth Third Bancorp increased its position in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in Krystal Biotech by 8,950.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock valued at $25,000 after buying an additional 179 shares in the last quarter. Finally, First Horizon Advisors Inc. lifted its position in Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).